Spectrum Pharma says ‘lucanthone’ could treat lung cancer
Biopharmaceutical company Spectrum Pharmaceuticals, Inc., said this morning that preclinical data on lucanthone suggest the orally administered small molecule inhibitor of DNA repair could potentially be used for the treatment of lung cancer.
This entry was posted on Thursday, April 17th, 2008 at 1:18 pm and is filed under Research. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.